Fate Therapeutics, Inc.
FATE
|
$4.795
-4.86%
-5.11%
2.7M
|
Health Technology
(0.0% 1d) (-35.5% 1m) (-23.0% 1y) (0.0% 2d) (0.0% 3d) (-15.1% 7d) (-4.39% volume)
Earnings Calendar: 2024-02-26
Market Cap: $ 545,751,115
http://www.fatetherapeutics.com
Sec Filling | Patents | 178 employees
(US) Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products include immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
cancer immunotherapy
add to watch list Paper trade email alert is off
Press-releases
Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
Published: 2024-04-03 (Crawled : 19:00) - biospace.com/
FATE | $4.795 -4.86% -5.11% 2.7M
|
Health Technology
|
| O: -0.29%
H: 7.52%
C: 3.39%
conference therapeutics
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-04-02 (Crawled : 20:00) - globenewswire.com
FATE | $4.795 -4.86% -5.11% 2.7M
|
Health Technology
|
| O: -0.29%
H: 7.52%
C: 3.39%
award nasdaq therapeutics employee
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
Published: 2024-03-19 (Crawled : 12:30) - globenewswire.com
FATE | $4.795 -4.86% -5.11% 2.7M
|
Health Technology
|
| O: -2.98%
H: 6.59%
C: 2.49%
million offering therapeutics
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-03-05 (Crawled : 21:00) - globenewswire.com
FATE | $4.795 -4.86% -5.11% 2.7M
|
Health Technology
|
| O: 3.32%
H: 12.71%
C: 11.45%
award nasdaq therapeutics employee
Fate Therapeutics to Present at Upcoming March Investor Conferences
Published: 2024-03-01 (Crawled : 13:00) - globenewswire.com
FATE | $4.795 -4.86% -5.11% 2.7M
|
Health Technology
|
| O: 0.99%
H: 8.94%
C: 8.1%
therapeutics
Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
Published: 2024-02-26 (Crawled : 21:00) - globenewswire.com
FATE | $4.795 -4.86% -5.11% 2.7M
|
Health Technology
|
| O: 8.78%
H: 14.15%
C: -1.32%
business year therapeutics financial results
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-02-15 (Crawled : 13:00) - globenewswire.com
FATE | $4.795 -4.86% -5.11% 2.7M
|
Health Technology
|
| O: 2.16%
H: 8.6%
C: 6.79%
conference year therapeutics financial results
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-02-02 (Crawled : 21:00) - globenewswire.com
FATE | $4.795 -4.86% -5.11% 2.7M
|
Health Technology
| Email alert
Add to watchlist
nasdaq awards therapeutics employee
Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors
Published: 2024-01-08 (Crawled : 13:00) - globenewswire.com
FATE | $4.795 -4.86% -5.11% 2.7M
|
Health Technology
|
| O: 0.8%
H: 13.16%
C: 8.42%
ft825 tumors trial therapeutics advanced
Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2023-12-13 (Crawled : 22:00) - globenewswire.com
FATE | $4.795 -4.86% -5.11% 2.7M
|
Health Technology
|
| O: 5.22%
H: 7.09%
C: 5.67%
nasdaq grants therapeutics employee
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
| 0001104659-24-038585 | 4 | 2024-03-26 | 2024-03-21 | Buy | A | 3636364 | 3893674 |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 67% | 33% |
Top 10 Gainers
Last 48 Hours Insiders Buying
RXO P 200000 | $19.37 2.32% 0.0% 1M
|
n/a
|
23:00
RKT P 380 | $11.68 1.3% 0.17% 1.9M
|
Finance
|
22:30
HROW P 29400 | $10.43 -3.87% -4.03% 680K
|
Health Technology
|
22:30
BCDA P 2750 | $0.377 -1.4% 97K
|
Health Technology
|
22:00
RMCF | $3.67 3.38% 3.27% 11K
|
Consumer Non-Durables
|
20:10